Horizon has entered into a number of partnerships to expand its product and service offerings and to insure that its technologies are available globally.
Sirion Biotech GMBH is a German based biotechnology company that supplies sophisticated viral vector and cell modelling platforms for target identification and drug screening.
Horizon has entered into a supply and distribution collaboration with Sirion to offer their RNAiONE™ shRNA generation platform as a custom service, which reliably produces shRNAs with a gene silencing efficiency often greater than 90%. This platform is a validation system that delivers shRNA sequences, transduction-ready lentiviruses or treated knockdown cell pools. Inducible knock-down and over-expression systems are also available, offering a valuable tool for functional gene analysis and to help deal with the adaptive capacity of cells.
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services.
Horizon Discovery works in collaboration with Transgenomic via its Horizon Diagnostics division, supplying them with Quantitative Molecular Reference Standards in both gDNA (genomic DNA) and FFPE (formalin fixed paraffin embedded) formats. These reference standards provide Transgenomic with invaluable tools to validate the efficacy of their molecular diagnostic technologies.
AstraZeneca is a multinational pharmaceutical and biologics company with operations in over 100 countries and is one of the largest pharmaceutical companies in the world.
Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.
Horizon is supplying their expertise in synthetic lethal screens and validation to AstraZeneca to allow them to broaden their oncology research efforts beyond their own internal capabilities, providing a strong base to launch their pre-clinical and clinical research efforts.
Desktop Genetics (DTG) is a bioinformatics company founded with a mission to build fully customizable software tools for life science companies. Their flagship product is AutoClone™, an innovative tool created to simplify the management and deployment of DNA assets within and between labs.
DTG has developed a proprietary CRISPR design platform for use in Horizon’s GENASSIST™ precision genome engineering tool offer. The platform is being used to quickly identify the best guide-RNAs in the human genome for each gene editing task.
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically-defined cancer subsets.
Horizon is working with Blueprint to support their “New Targets” discovery platform by employing precision genome engineering of patient relevant cell line models and expertise in the field of oncology to support Blueprint’s drive to develop genetically tailored, highly selective cancer therapies.
Boehringer Ingelheim, Horizon is in a 5 year oncology research collaboration with Boehringer Ingelheim, providing use of their Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead optimization and pre-clinical stages to elucidate their anti-cancer properties and help guide drug discovery programs. Horizon is evaluating compounds across a broad panel of X-MAN isogenic models and selected 2D/3D phenotypic assays, and provides access to its custom cell line generation services to support the programs.
Bayer AG is a German chemical and pharmaceutical giant that had been at the forefront of pharmaceutical development for over 150 years.
Horizon’s role in the partnership is to develop pre-clinical cell line models that will support Bayer’s oncology research and development programs, using Horizon’s precision genome editing technology, GENESIS™. Horizon provides Bayer with high quality cell lines that more accurately represent the disease-relevant mutations found in human tumors, which provide invaluable models to identify novel potential drug candidates to address cancer.
H3 Biomedicine Inc. is a biopharmaceutical company specializing in the discovery and development of oncology treatments.
Horizon is working with H3 Biomedicine to identify and validate critical cancer genome targets whose modulation will have meaningful clinical effect. Based on targets validated in partnership with Horizon, H3 Biomedicine will then carry out early target discovery through to preclinical research and the clinical research (via Eisai Pharmaceuticals), while Horizon will continue to implement its discovery toolbox to run alongside and support H3 Biomedicine’s internal research programs.
Promega is a leader in providing innovative solutions and technical support to the life sciences industry offering more than 2,000 products which enable scientists worldwide to advance their research in genomics, proteomics, and cellular analysis.
The objective of the partnership is to develop new endogenous pathway imaging and reporter models by incorporating Promega’s NanoLuc™ and HaloTag® technologies into X-MAN™ cell lines to generate unique screening tools that exploit the ability to monitor the activity levels and localisation of specific genes and proteins in live cells at the endogenous level.
The first 30 assay kits were launched in Q4, 2012.
ATCC is a private, non-profit biological resource center and research organization whose mission focuses on the acquisition, authentication and production of cell lines.
Horizon’s partnership with ATCC is based on the provision of X-MAN™ isogenic cell lines through ATCC to their large academic client base in conjunction with their established sold tumor cancer panels thus significantly extending the reach of X-MAN™ cell lines into academic research.
SPI is a wholly owned subsidiary of Sumitomo Corporation and is an integrated service company specializing in the area of pharmaceutical development and commercialization.
Horizon has entered into an agreement with SPI to identify business opportunities in Japan.
Crown Bioscience Inc. is a contract research service company focused on advancing anti-cancer therapeutics through the preclinical and drug development stages.
The partnership between Horizon and Crownbio will allow their xenograft and other pre-clinical cancer models to exploit the genetic definition of Horizon’s X-MAN™ isogenic cell lines in vivo, to the benefit of customers of both companies.
The European Molecular Genetics Quality Network (EMQN) is a provider of External Quality Assessment (EQA) services which are essential for any laboratory seeking to maintain and provide a quality service.
Horizon provides genetically defined isogenic human cell line reference standards, in carefully calibrated and quality controlled mutant vs. normal stochiometries, for distribution to molecular diagnostic laboratories around the world as part of EMQN’s annual EQA schemes.
UK NEQAS ICC (the UK National External Quality Assessment Service) is a leader in diagnostic proficiency assessment. They ensure optimal patient care by providing a comprehensive external quality assessment service in laboratory medicine.
UK NEQAS ICC receives an exclusive license to distribute isogenic reference standards related to certain lung cancer biomarkers in the UK and in Europe for the sole purpose of proficiency testing within its quality assessment program.
EntroGen, Inc is a biotechnology company developing novel genotyping assays in the areas of pharmacogenomics and oncology.
Horizon has developed a range of key FFPE-based isogenic reference standards that are assisting with the development of EntroGen’s molecular assays.
The University of Torino is a key partner along with Horizon in COLTHERES, a consortium of EU clinical centers and translational researchers. Professor Alberto Bardelli from the University of Torino School of Medicine in Turin, and co-founder of Horizon Discovery, is lead investigator for the Consortium.
COLTHERES is a four-year program that will use comprehensively molecularly-annotated colon cancers as a ‘test-bed’ to define specific biomarkers of response or resistance to signalling pathway agents.
Horizon Discovery and the Institute of Cancer Research have formed a collaboration aimed at rapidly screening the human genome for novel drug targets that selectively kill cancer cells.
ICR scientist Professor Alan Ashworth, Director of the Breakthrough Breast Cancer Research Center at the ICR, has previously demonstrated the concept of ‘synthetic lethality’ which is now being applied to Horizon’s SyntheTx high-throughput screening platform.
Horizon has a commercial agreement with Novartis Institute of Biomedical Research relating to the ongoing access to a panel of X-MAN™ cell lines. The collaboration between the companies, which began in November 2009, and successfully completed an 18 month pilot program in 2011 has now been progressed to generate 30-50 new X-MAN™ cell lines annually.
Horizon has a long history of working with key researchers at Johns Hopkins University in the area of rAAV gene-editing technology. Dr. Bert Vogelstein is the source of many of Horizon’s initial set of cell lines, and Dr. Ben Ho Park is working with Horizon on drug repositioning and acts as an advisor through our S.A.B.
Horizon and the lab of Steve Jackson at the Gurdon Institute in the University of Cambridge are working together to create isogenic cell line models using Horizon’s rAAV gene-editing technology to create endogenous gene tags/ knockouts/ mutations as part of Horizon’s Centers of Excellence program.
The focus of the Jackson lab is to better understand how cells detect DNA damage and signal its presence to the DNA repair, transcription and cell cycle machineries. Loss of these pathways is important in many diseases including sporadic and hereditary cancer.
Horizon has an extensive collaboration with Washington University St Louis, one of Horizon’s premier Centers of Excellence. Washington University is establishing a core facility that will create isogenic cell lines using rAAV that will benefit a number of academic groups at the university.
This facility will also be able to use rAAV to translate information that arises from genomic studies on specific diseases, such as cancer, performed at the BRIGHT Institute at Washington University into endogenous cell line models.
Paragraph explaining benefits of Biocair×